Shirin Haghighi1, Hadi Kasbkar, Keihan Esmaeilpour, Mehrdad Yasaei. 1. Department of Oncology, Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Email : mehrdad.yasaei@gmail.com.
Abstract
BACKGROUND: Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide. Gastric cancer develops more frequently among elderly. The oxaliplatin/5FU/leucovorin (FOLFOX) regimen has shown a notable activity against gastric cancer. AIM: To evaluate the responses and complications of FOLFOX4 regimen as first line chemotherapy in elderly patients with advanced gastric cancer. MATERIALS AND METHODS: From October 2014 to November 2015, a total of 21 patients with metastatic or local AGC (advanced gastric cancer) were analyzed. All patients were administered a FOLFOX4 regimen consisting of a 2h infusion of oxaliplatin 85 mg/m2 (day 1), continuous infusion of 1000mg/ m2 5Fu in 24h., and leucovorin 200 mg/m2 in 2h infusion as a firstline chemotherapy. RESULTS: A total of 18 patients were assessable for efficacy and toxicity. One of 18 patients achieved a complete response, and 12 had partial responses, giving an overall response rate of 72.6%. Three (16%) patients demonstrated stable disease and 2 (12%) progression. The median progression free survival was 7.3 months, and the median overall survival was 11.9 months. One patient had grade 3 neuropathy. No other grade 3 or 4 NCICTC were seen. CONCLUSIONS: The FOLFOX4 regimen used in our study was both active and acceptable for AGC in elderly patients as neoadjuvant and main therapy.
BACKGROUND:Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide. Gastric cancer develops more frequently among elderly. The oxaliplatin/5FU/leucovorin (FOLFOX) regimen has shown a notable activity against gastric cancer. AIM: To evaluate the responses and complications of FOLFOX4 regimen as first line chemotherapy in elderly patients with advanced gastric cancer. MATERIALS AND METHODS: From October 2014 to November 2015, a total of 21 patients with metastatic or local AGC (advanced gastric cancer) were analyzed. All patients were administered a FOLFOX4 regimen consisting of a 2h infusion of oxaliplatin 85 mg/m2 (day 1), continuous infusion of 1000mg/ m2 5Fu in 24h., and leucovorin 200 mg/m2 in 2h infusion as a firstline chemotherapy. RESULTS: A total of 18 patients were assessable for efficacy and toxicity. One of 18 patients achieved a complete response, and 12 had partial responses, giving an overall response rate of 72.6%. Three (16%) patients demonstrated stable disease and 2 (12%) progression. The median progression free survival was 7.3 months, and the median overall survival was 11.9 months. One patient had grade 3 neuropathy. No other grade 3 or 4 NCICTC were seen. CONCLUSIONS: The FOLFOX4 regimen used in our study was both active and acceptable for AGC in elderly patients as neoadjuvant and main therapy.
Authors: Hongying Wu; Xiaomei Miao; Yan Liu; Shu Zhang; Chaohui Li; Jie Hao Journal: Evid Based Complement Alternat Med Date: 2022-05-05 Impact factor: 2.650
Authors: Mohammad Ali Mashhadi; Zahra Sepehri; Ali Reza Bakhshipour; Ali Zivari; Hossein Ali Danesh; Hasan Ali Metanat; Azra Karimkoshteh; Seyed Mehdi Hashemi; Hossein Rahimi; Zohre Kiani Journal: Int J Hematol Oncol Stem Cell Res Date: 2016-10-01
Authors: Kohei Shitara; Toshihiko Doi; Hisashi Hosaka; Peter Thuss-Patience; Armando Santoro; Federico Longo; Ozgur Ozyilkan; Irfan Cicin; David Park; Aziz Zaanan; Carles Pericay; Mustafa Özgüroğlu; Maria Alsina; Lukas Makris; Karim A Benhadji; David H Ilson Journal: Gastric Cancer Date: 2022-01-08 Impact factor: 7.701
Authors: Xiaomei Miao; Hongying Wu; Yan Liu; Shu Zhang; Chaohui Li; Jie Hao Journal: Evid Based Complement Alternat Med Date: 2022-07-30 Impact factor: 2.650